Long intergenic non-protein coding RNA 1239 (LINC01239)

Long intergenic non-protein coding RNA 1239 (LINC01239) is a **long intergenic non-coding RNA** (lincRNA), a subclass of long non-coding RNAs autonomously transcribed from regions of the genome that do not overlap protein-coding genes[1][3][5]. LINC01239 is primarily defined by its lack of protein-coding capacity and its annotation as a distinct RNA transcript (NCBI Gene ID: 441389). Like other lincRNAs, it is believed to play roles in **fine-tuning gene expression, chromatin architecture, and transcriptional regulation**, potentially contributing to tissue specificity and disease processes. Evidence suggests it may be **differentially expressed in cancers** and participate in regulatory networks affecting tumor progression[1][6]. However, LINC01239 itself is *not classified as a direct druggable therapeutic target* (e.g., enzyme, receptor, transporter), and there are currently **no established drugs or targeted mechanisms of action** associated with this RNA. Its emerging association with cancer makes it a **candidate biomarker for disease or prognosis** rather than a classical small-molecule or biologic drug target[6][1][5].

Other names

LINC01239